To hear about similar clinical trials, please enter your email below
Trial Title:
Impact of the Experience of Anaesthetists in Changing Ventilation Strategies During Panendoscopy on the Incidence of Intraoperative Hypoxaemia
NCT ID:
NCT05601570
Condition:
ENT Tumor
Conditions: Official terms:
Hypoxia
Conditions: Keywords:
Panendoscopy
High Flow Nasal Oxygen
face mask ventilation
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Retrospective
Summary:
High Flow Nasal Oxygen Therapy (HFNO) is a new oxygenation tool that is becoming
increasingly widespread in perioperative anaesthesia. The benefits of this oxygenation
tool are based on different physiological principles. These include the reduction of dead
space by "flushing" the nasopharyngeal cavities, positive airway pressure and the warming
and humidification of inspired air. In addition, the high flow rates used ensure that the
patient's inspiratory demand is covered, allowing for the delivery of oxygen-enriched and
controlled air. It is simple to use, with the only parameters to be set being gas flow
and FiO2. The use of HFNO appears to allow a prolongation of apnoea time without
desaturation in apneic ventilation.
Mainly studied in ENT surgery because of the interest that this oxygenation strategy
presents with the absence of recourse to oro-tracheal intubation (OTI), several authors
will use it in the framework of micro-laryngoscopy surgery in suspension. However, its
use as an oxygenation strategy during panendoscopy has been little explored. Panendoscopy
is a common procedure that requires deep and short anesthesia. The main challenge is the
sharing of the airway between the anesthesia team and the surgical team. Learning to use
this new method or the impact of operator experience has never been explored.
Detailed description:
Currently, there are several strategies to ensure oxygenation during this specific type
of ENT management:
- Mechanical ventilation with oro-tracheal intubation (OTI)
- Face mask ventilation (FMV)
- Jet ventilation
- HFNO Each of these methods has advantages and disadvantages, which explains why
there are no clear recommendations to date on the preferred anesthesia and
oxygenation technique. Regardless of the method chosen, the risks remain significant
for the patient, particularly the risk of hypoxemia during a desaturation episode.
For several years, the strategy of oxygenation during panendoscopy and the number of
practitioners performing this procedure has evolved in our centre.
- 2017, with the arrival of the HFNO in the operating room.
- 2020, during the SARS-CoV2 pandemic, changes in the organisation of the
anaesthesiology department had to take place and the number of practitioners
performing this procedure increased significantly.
The main objective of this study was to evaluate the impact of the evolution periods of
the oxygenation strategies and the experience of the operators on the incidence of
patients with at least one intra-procedural hypoxemia (SpO2 < 90% for more than one
minute).
All patients who had a panendoscopy from 01 January 2015 to 31 December 2020 were
analysed. The anaesthetists in our centre are divided into different practice
specialties, so a small number of them regularly perform anaesthesia in ENT surgery. We
divided the anaesthetists who performed panendoscopies during the study period into two
categories in order to compare the incidence of severe hypoxaemia (SpO2 < 90%) among them
:
- Experienced anaesthetists (practitioner who has performed at least 30 panendoscopies
per year for two consecutive years)
- Non-experienced anaesthetists (practitioner who has performed at least one
panendoscopy per year and does not meet the criteria for expertise)
Criteria for eligibility:
Study pop:
All major patients receiving panendoscopy during the period 2015 - 2020 in our center
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- major patients receiving panendoscopy
Exclusion Criteria:
- panendoscopies performed in combination with another invasive procedure that may
alter anaesthetic management
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Centre Hospitalier Universitaire de Besançon
Address:
City:
Besançon
Zip:
25000
Country:
France
Start date:
April 10, 2024
Completion date:
October 30, 2024
Lead sponsor:
Agency:
Centre Hospitalier Universitaire de Besancon
Agency class:
Other
Source:
Centre Hospitalier Universitaire de Besancon
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05601570